Home » Topics » Immuno-oncology, BioWorld Science

Immuno-oncology, BioWorld Science
RSS

Therapeutic antibodies with reduced side effects presented by Isis Innovation

March 9, 2004

European orphan drug status for Revlimid in MDS

March 5, 2004

Long-term survival data for Rencarex in metastatic renal cell carcinoma

March 5, 2004

New round of financing at Igeneon to advance lead candidates

March 4, 2004

Advanced Viral Research reports in vitro biologic effects of AVR-118

March 3, 2004

Promising results found for an autologous melanoma cancer vaccine

March 2, 2004

SGN-30 receives orphan drug designation for T-cell lymphomas

March 1, 2004

Micromet and Boehringer Ingelheim collaborate on MT-201 manufacturing

Feb. 27, 2004

Seattle Genetics and Abbott sign manufacturing agreement for SGN-30

Feb. 26, 2004

Enrollment scheduled to conclude in pivotal MyVax trial

Feb. 23, 2004

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 22, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 22, 2026.
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...
Neurotrimin unveiled as marker in intellectual disability
BioWorld Science
Neurotrimin (NTM) is a member of the IgLON family, the disruption of which has been tied to emotional learning deficits and anxiety-like behavior in animal...
Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal
BioWorld
With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...